Navarro VM

Idioma: Español
Referencias bibliográficas: 27
Paginas: 152-155
Archivo PDF: 58.17 Kb.

RESUMEN

Las neoplasias mieloproliferativas son un conjunto de enfermedades caracterizadas por la presencia de re-arreglos genéticos o mutaciones somáticas en los genes que codifican para proteínas o receptores que están en relación con la actividad proteica cinasa en la tirosina, como el BCR/ABL, JAK 2 y RFCDP 1, confiriéndole ventaja proliferativa y superviviencia al clon neoclásico mieloide de cualquiera de sus tipos granulocitico, eritroide o megacatiocitco. La leucemia mieloide crónica se caracterizada por la coexistencia de t(9;22) o cromosoma Filadelfia, cuyo marcador molecular es suficiente para que se inicie esta enfermedad y el cual puede utilizarse para la investigación de enfermedad mínima residual posterior a la terapia con blanco en la proteína quimérica resultante.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Dameshek W. Some speculations on the myeloproliferative síndromes. Blood 1951;6:372-375.

2. Tefferi A and Vardiman J. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008;22:14-22.

3. Hehlmann R, Hochhaus A and Baccarani M. European LeukemiaNet. Chronic myeloid leukaemia. Lancet 2007;370:342-350.

4. Hasserjian R. Chronic Myelogenous Leukemia. Texas. Dan Jones Houston 2010 193-211.

5. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-1148.

6. Kralovics R, Passamonti F, Buser A, Teo S, et al. A gain-offunction mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-1790.

7. Faderl S, Talpaz M, Estrov Z, O’Brien S, et al. The biology of chronic myeloid leukemia. N Engl J Med 1999;341:164-172.

8. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960;132:1497.

9. Goldman J, Melo J. Chronic Myeloid Leukemia. Advances in Biology and New Approaches to Treatment. N Engl J Med 2003;349:1451-1464.

10. Vardiman J, Melo J, Baccarani M, Thiele J. Chronic myelogenous leukaemia, BCR-ABL 1 positive. Lyon. Swerdlow S, Campo E, Harris N, Jaffe E, Pileri S, Stein H 2008;pp:32-37.

11. Roy L, Guilhot J, Krahnke T, Guerci-Bresler A, et al. Survival advantage from imatinib compared with the combination interferon-plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood 2006;108:1478-1484.

12. Marcucci G, Perrotti D, Caligiuri M. Understanding the Molecular Basis of Imatinib Mesylate Therapy in Chronic Myelogenous Leukemia and the Related Mechanisms of Resistance. Clin Cancer Res 2003;9:1333-1337.

13. Hughes T, Deininger M, Hochhaus A, Branford S, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006;108:28-37.

14. Thiele J, Kvasnicka H, Orazi A, Tefferi A, Birgegard G. Polycythaemia vera Lyon. In: Swerdlow S, Campo E, Harris N, Jaffe E, et al. FALTAN DATOS 2008;pp:40-43.

15. Tefferi A, Skoda R, Vardiman J. Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics. Nat Rev Clin Oncol 2009;6:627-637.

16. Chen G, Prchal J. Polycythemia vera and its molecular basis: An update. Best Pract & Res Clin Haematol 2006;19:387-397.

17. Streiff M, Smith B, Spivak J. The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group: a survey of American Society of Hematology members’ practice patterns. Blood 2002;99:1144-1149.

18. Tefferi A. Essential thrombocythemia: scientific advances and current practice. Curr Opin Hematol 2006;13:93-98.

19. Thiele J, Kvasnicka H, Orazi A, Tefferi A, Gisslinger H. Essential thrombocythaemia. Lyon. In: Swerdlow S, Campo E, Harris N, et al. FALTA EL TÍTULO 2008;pp:48-50.

20. Antonioli E, Guglielmelli P, Pancrazzi A, Verrucci M, et al. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 2005;19:1847-1849.

21. Thiele J, Kvasnicka H, Tefferi A, Barosi G, et al. Primary myelofibrosis. Lyon. In. Swerdlow S, Campo E, Harris N, Jaffe E, et al. FALTAN DATOS 2008;pp:44-47.

22. Barosi G, Bergamaschi G, Marchetti M, et al. Splenomegaly and leukemic transformation in primary myelofibrosis JAK2 V617F mutational status predicts progression to large. Blood 2007;110:4030-4036.

23. Tefferi A. Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol 2005;23:8520-8530.

24. Bain B, Gilliland D, Vardiman J. and Horny H. Chronic eosinophilic leukaemia not otherwise specified. Lyon. Swerdlow S, Campo E, Harris N, Jaffe E, Pileri S, Stein H 2008;pp:48-50.

25. Tefferi A, Patnaik M and Pardanani A. Eosinophilia: secondary, clonal and idiopathic. Br J Haematol 2006;133:468-492.

26. Horny H, Metcalfe D, Bennett J. and Bain B. Mastocytosis. Lyon. Swerdlow S, Campo E, Harris N, Jaffe E, Pileri S, Stein H 2008;pp:57-63.

27. Garcia-Montero A, Jara-Acevedo A, Teodosio C, Sanchez M, Nunez R, Prados A, et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Networkon Mastocytosis (REMA) in a series of 113 patients. Blood. 2006;108:2366-2372.